台股 » 個股 » 美時 » 籌碼相關 » 券商分點績效 » 券商分點個股進出

美時

(1795)
可現股當沖
  • 股價
    234.5
  • 漲跌
    --
  • 漲幅
    0.00%
  • 成交量
    1,104
  • 產業
    上市 生技醫療類股
  • 626人加入追蹤

    立即追蹤

  • 本地時間:14:30(已收盤)

     
美時 (1795)籌碼相關-香港上海匯豐 券商分點個股進出
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

Created with Highstock 1.3.7Zoom券商分點個股進出嗨投資 histock.tw06/2207/0607/2208/0208/1608/3009/1409/2810/1210/2611/0811/2212/0612/2001/0401/1802/0802/2203/0805/1805/2803/2004/0104/1404/2405/0605/30160180200220240260280Jul '24Sep '24Nov '24Mar '25May '2560d90dAll

香港上海匯豐 券商分點個股進出

日期買進張數買進均價賣出張數賣出均價收盤價買賣超60日均量成交佔比 大量交易提示
2025/05/2821235.2900.00234.50211,7171.22%
2025/05/2736233.4700.00235.00361,6762.15%
2025/05/2200.0012226.67226.50-121,625-0.74%
2025/05/1400.003227.00227.00-31,776-0.17%
2025/05/0900.0013229.00229.00-131,718-0.76%
2025/05/026226.1700.00227.5061,7850.34%
2025/04/282216.5000.00219.5021,7770.11%
2025/04/252212.7500.00214.5021,8120.11%
2025/04/244211.2500.00210.0041,8100.22%
2025/04/2314212.6100.00213.00141,8150.77%
2025/04/2236206.6400.00206.50361,8211.98%
2025/04/177213.4300.00214.5071,8470.38%
2025/04/166216.5800.00216.0061,8410.33%
2025/04/153219.6700.00220.5031,8200.16%
2025/04/143216.6700.00218.0031,7910.17%
2025/04/1100.00115205.18212.00-1151,730-6.64% 大賣/鉅額交易
2025/04/0715209.0000.00209.00151,4891.01%
2025/04/0100.004234.00234.00-41,551-0.26%
2025/03/278250.1900.00251.0081,4850.54%
2025/03/170256.0000.00255.5001,5460.00%
2025/03/061264.5000.00263.0011,6030.06%
2025/03/031270.5000.00268.5011,7070.06%
2025/02/2700.007274.50274.50-71,705-0.41%
2025/02/21327275.7200.00275.003271,78618.31% 大買/鉅額交易
2025/02/14552287.1400.00286.005521,94528.38% 大買/鉅額交易
2025/02/1100.0050279.01276.50-502,102-2.38%
2025/02/0300.004259.00259.00-42,025-0.20%
2025/01/2200.003258.00258.00-32,023-0.15%
2025/01/2000.002252.50258.00-22,023-0.10%
2025/01/1600.008260.75262.50-81,996-0.40%
2025/01/031266.0000.00264.5012,0350.05%
2025/01/021269.0100.00266.5012,0300.05%
2024/12/301271.0000.00271.0012,0360.05%
2024/12/271.6272.8000.00271.501.62,0600.08%
2024/12/201.8262.2300.00260.501.82,0520.09%
2024/12/191.3261.1200.00260.501.32,0620.06%
2024/12/181.6260.1600.00263.501.62,0690.08%
2024/12/171258.5000.00259.0012,0570.05%
2024/12/115268.5000.00266.0052,0810.24%
2024/12/052286.0000.00286.0022,0980.10%
2024/12/044.1287.6700.00287.004.12,0950.20%
2024/12/031289.0000.00288.0012,1150.05%
2024/12/021.3293.3300.00286.001.32,1090.06%
2024/11/291.3277.7900.00291.501.32,0840.06%
2024/11/2520285.505285.50285.50151,9850.76%
2024/11/217286.5000.00285.5071,9670.36%
2024/11/192281.0000.00285.5021,9220.10%
2024/11/147285.5700.00282.0071,9560.36%
2024/10/1800.002259.00259.00-22,160-0.09%
2024/10/1400.00343252.36255.50-3432,292-14.96% 大賣/鉅額交易
2024/10/0900.00105255.84255.50-1052,530-4.15% 大賣/鉅額交易
2024/10/0100.00129258.50261.00-1292,687-4.80% 大賣/鉅額交易
2024/09/2000.0085268.96268.50-853,430-2.48%
2024/08/3000.001287.00287.00-13,793-0.03%
2024/08/2800.004285.50281.00-43,820-0.10%
2024/07/1890287.9400.00288.50904,8001.87%
2024/06/1475284.4700.00284.00756,3361.18%
2024/06/1100.005287.50287.50-56,382-0.08%
2024/06/0500.001286.50292.50-16,378-0.02%
〈焦點股〉美時Bosutinib獲台灣TFDA核准上市 股價走揚攻季線Anue鉅亨-2天前
美時與上海復宏漢霖合作 將在韓國銷售抗 PD-1抗體新藥UDN聯合新聞網-2025/04/25
美時 相關文章